Sec Form 3 Filing - Gryaznov Sergei @ MAIA Biotechnology, Inc. - 2022-07-27

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Gryaznov Sergei 2. Issuer Name and Ticker or Trading Symbol MAIA Biotechnology, Inc. [ MAIA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Scientific Officer (Last) (First) (Middle) 444 WEST LAKE STREET, SUITE 1700 3. Date of Earliest Transaction (MM/DD/YY) 07/27/2022 (Street) CHICAGO, IL60606 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 21,511( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options $ 1.8 ( 2 ) 11/30/2029 Common Stock 200,000 D Stock Options $ 1.8 ( 3 ) 11/30/2029 Common Stock 58,000 D Stock Options $ 1.8 ( 4 ) 04/01/2030 Common Stock 54,000 D Stock Options $ 1.8 ( 5 ) 11/02/2030 Common Stock 236,493 D Stock Options $ 1.8 ( 6 ) 12/31/2030 Common Stock 23,695 D Stock Options $ 1.83 ( 7 ) 04/15/2031 Common Stock 164,662 D Stock Options $ 1.83 ( 8 ) 04/15/2031 Common Stock 78,413 D Stock Options $ 1.83 ( 9 ) 03/31/2031 Common Stock 23,078 D Stock Options $ 1.83 ( 10 ) 04/15/2031 Common Stock 50,000 D Stock Options $ 1.83 ( 11 ) 06/30/2031 Common Stock 7,529 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Gryaznov Sergei 444 WEST LAKE STREET, SUITE 1700 CHICAGO, IL60606 Chief Scientific Officer Signatures /s/ Sergei M. Gryaznov 07/27/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Mr. Gryaznov beneficially owns 21,511 shares of common stock. ( 2 )Represents an option to purchase shares of Common Stock granted pursuant to the 2018 Stock Option Plan. These options fully vested on .December 1, 2019. ( 3 )Represents an option to purchase shares of Common Stock granted pursuant to the 2018 Stock Option Plan. These options vested in four equal monthly installments on December 1, 2019. ( 4 )Represents an option to purchase shares of Common Stock granted pursuant to the 2018 Stock Option Plan. 6,055 of these options vested on April 30, 2020 and 47,945 of these options vested on January 1, 2021. ( 5 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on November 3, 2020. ( 6 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options vested in 90 equal daily instalments beginning on January 1, 2021. ( 7 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on May 20, 2021. ( 8 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on May 20, 2021. ( 9 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options vested in 90 equal daily instalments beginning on April 2, 2021. ( 10 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options vested in 36 equal monthly instalments beginning on January 1, 2021. ( 11 )Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options fully vested on July 1, 2021.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.